IQVIA's blowout quarter revealed a growing contract backlog, which is the strongest possible signal of future revenue because these orders are locked in and will be billed over the coming years. The broader healthcare sector has been quiet while mega-cap

Verdict: The IQVIA backlog story is real, but the trade is 15% early

The idea's core claim — that IQVIA is a demand-verified, under-owned compounder due for institutional rotation — has genuine support: fiscal 2025 delivered $16.3B of revenue (up 5.9%), $1.36B of net income, $2.05B of free cash flow, and a 99th-percentile free-cash-flow rank among Health Care peers, while the share count fell from 176.1M to 166.9M. But the freshest evidence cuts against the timing. The most recent 13F cycle (June 30, 2026 report period, filing deadline passed) shows net open-market insider selling of roughly $29.2M, net margin compressed to 6.6% from 8.3% sequentially, debt-to-equity rose to 2.25, and the stock closed at $256.05 with the 14-day RSI at 77.09 — 32 points above the setup's own 45 trigger and 15% above the $217.35 50-day EMA entry. The strongest point for the trade is the elite cash generation backing the backlog narrative; the strongest point against is that insiders were net sellers and the entry conditions are nowhere near being met. A verified insider return to net buying, or a September 30 filing that flips the flow, is the fact that would change this verdict. (Scope note: the rule-based setup could not be evaluated because IQVIA daily market-data coverage could not be verified, so this read rests on live levels, fundamentals, and positioning.)

Trade now: no entry — IQVIA is extended above every trigger

IQVIA closed at $256.05, and the setup is a **wait**. The strategy wants a pullback long: price below the 50-day EMA (now $217.35), above the lower Bollinger band (the 20-day band sits at $237.12, so this condition is currently met), a 14-day RSI at or below 45, and the RSI having just crossed back above 40. Right now only the band condition is satisfied. Price sits $38.70 above the EMA — a 15.1% pullback needed — and the RSI at 77.09 is more than 32 points above the 45 ceiling. Nothing here is close to triggering today. If an entry did fill, the exits are mechanical: a 2% stop loss versus a 4% take-profit (a 2-to-1 reward-to-risk ratio), with a hard time exit after 40 trading days. Support-based exits use the second-ranked support near $240 and the first-ranked resistance at $251.36 — note that resistance currently sits below the price, a sign of how extended the tape is. One scope note: daily market-data coverage for IQVIA could not be verified within the analysis retry window, so the frozen rule set could not be evaluated and no robust parameter setup was established. That does not change today's action — the live levels above already say wait. Concretely, "wait" means: do not chase; set alerts at $217.35 (price) and 45 (RSI) and re-read this setup only when both are in range. The thesis (a backlog-driven, under-owned healthcare name due for institutional rotation) argues patience will be rewarded, but the numbers argue the trade is late, not early: the stock is at its range high, up 63.4% from the range low, and the 50-day simple average at $211.35 confirms how far price has run above trend.

A Backlog Story That the Numbers Actually Back Up

The core of the idea — that IQVIA is a demand-verified business flying under the radar — has real fundamental support. Fiscal 2025 closed with $16.3B of revenue, up 5.9% year over year, net income of $1.36B, and $2.1B of free cash flow. Against a Health Care peer set of roughly 660-990 companies, those results place IQVIA in the 99th percentile for free cash flow, the 87th percentile for operating margin (13.4%), and the 84th percentile for return on equity (20.9%). This is not a turnaround story hoping for demand; the demand is already in the reported numbers, which is consistent with the growing-contract-backlog framing in the cited Yahoo Finance piece on the blowout quarter. The trajectory also fits the thesis. Quarterly revenue has climbed steadily from $3.83B in Q1…

Scores

• Conviction score breakdown: 41
• Thesis support: 55
• Trade readiness: 15
• Risk quality: 40
• Fundamentals trend: 55

Watch items

• IQV — RSI (14)
• IQV — Close vs 50-day EMA
• IQV — Close vs lower Bollinger (20)
• IQV — Insider net open-market activity
• IQV — Next quarterly earnings report
• IQV — Debt-to-equity
• IQV — Price below EMA (50)
• IQV — Price above Bollinger (20)
• IQV — RSI (14) below 45
• IQV — RSI (14) crossed above 40